Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 – 2014)

Bibliography

• Lerner AB, Case JD, Takahashi Y, et al. Isolation of melatonin: the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958;80:2587
   Web of Science ®Google Scholar
• Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014;71:2997-3025
   PubMed Web of Science ®Google Scholar
• Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008;85:335-53
   PubMed Web of Science ®Google Scholar
• Carpentieri A, Díaz de Barboza G, Areco V, et al. New perspectives in melatonin uses. Pharmacol Res 2012;65:437-44
   PubMed Web of Science ®Google Scholar
• Sanchez-Barcelo E, Mediavilla MD, Tan DX, Reiter RJ. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010;17:2070-95
   PubMed Web of Science ®Google Scholar
• Dubocovich ML, Delagrange P, Krause DN, et al. International Union of basic and clinical pharmacology. LXXV. Nomenclature, classification and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010;62:343-80
   PubMed Web of Science ®Google Scholar
• Slominski RM, Reiter RJ, Schlabritz-Loutsevich N, et al. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 2012;351:152-66
   PubMed Web of Science ®Google Scholar
• Hardeland R. Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors 2009;35:183-92
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Rosales-Corral S, Manchester LC. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem 2013;13:373-84
   PubMed Web of Science ®Google Scholar
• Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother 2012;13:895-905
   PubMed Web of Science ®Google Scholar
• Zlotos R, Jockers R, Cecon E, et al. MT1 and MT2 melatonin receptors: ligands, oligomers and therapeutic potential. J Med Chem 2014;57:3161-85
   PubMed Web of Science ®Google Scholar
• Leclerc V, Ettaoussi M, Rami M, et al. Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3. Eur J Med Chem 2011;46:1622-9
   PubMedGoogle Scholar
• Spadoni G, Bedini A, Rivara S, Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther 2011;17:733-41
   PubMed Web of Science ®Google Scholar
• Zemlan FP, Mulchahey JJ, Scharf MB, et al. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005;66:384-90
   PubMed Web of Science ®Google Scholar
• Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4:487-504
   PubMed Web of Science ®Google Scholar
• Ferguson SA, Rajaratnam SMW, Dawson D. Melatonin agonists and insomnia. Expert Rev Neurother 2010;10:305-18
   PubMed Web of Science ®Google Scholar
• Requis Pharmaceutical, Inc. Antihistamines combined with dietary supplements for improved health. US0199417; 2014
   Google Scholar
• Casal Y, Garzov RE. Drug composition for the treatment of insomnia. WO109695; 2012
   Google Scholar
• Nestec SA. Methods and compositions useful for promoting sleep in animals. US0273176; 2013
   Google Scholar
• Nestec SA. Compositions and methods for enhancing cognitive and related functions in animals. US0171303; 2012
   Google Scholar
• Tianjin Tiens Biolog Dev Co., Tianjin Tiens Life Sources Co Ltd; Tiens Group Co Ltd. Medlar and tuckahoe composition and preparation method thereof. CN102552536; 2012
   Google Scholar
• Guangzhou Gonghe Medicine Tecnology Co Ltd; Guangzhou Xiangkun Medicine Tecnology Co Ltd. Anti-insomnia composition, application of composition, multi-phase pulse immediate-release preparation prepared by use of composition and preparation method of preparation. CN103550775; 2014
   Google Scholar
• Dongguan Zhaoyan Biotechnology Co Ltd. Nutritional health-care product for improving agrypnia. CN102688416; 2012
   Google Scholar
• Keller RM. Formulation and method to induce a deep state of relaxation. WO166246; 2013
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Tricyclic compound and pharmaceutical use thereof. US8552037; 2013
   Google Scholar
• Koike T, Takai T, Hoashi Y, et al. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands. J Med Chem 2011;54:4207-18
   PubMed Web of Science ®Google Scholar
• Vanda Pharmaceuticals, Inc. Use of melatonin agonist for the treatment of sleep disorders including primary insomnia. US0136050; 2012
   Google Scholar
• Vanda Pharmaceuticals, Inc. Treatment of circadian rhythm disorders. US8785492; 2014
   Google Scholar
• Obshchestvo S Ogranichennoj Otvetstvennost’ju “Ehr Ehnd Di Farma”. Pharmaceutical composition for prevention and treatment of depressions. RU2011109649; 2012
   Google Scholar
• Parshin AN, Gilod VM. Method of treating adaptation disorders in patients with risk of suicidality. RU2506073; 2014
   Google Scholar
• Joshi N, Biswas J, Nath C, Singh S. Promising role of melatonin as neuroprotectant in neurodegenerative pathology. Mol Neurobiol 2014. 10.1007/s12035-014-8865-8
   Web of Science ®Google Scholar
• Polimeni G, Esposito E, Bevelacqua V, et al. Role of melatonin supplementation in neurodegenerative disorders. Front Biosci (Landmark ed) 2014;19:429-46
   PubMed Web of Science ®Google Scholar
• Bennett M, Peller G. Compositions and methods for treating traumatic brain injury. CA2799127. 2014
   Google Scholar
• Centrum Medyczne Ksztalcenia Podyplomowego - Uniwersytet Warszawski. Novel hybrid cholinesterase inhibitors. US8841453; 2014
   Google Scholar
• Regents of University of Minnesota. Ischemia/reperfusion protection compositions and methods of using. US8728532; 2014
   Google Scholar
• Jacobson KA. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 1998;19:184-91
   PubMed Web of Science ®Google Scholar
• Korea University Research and Business Foundation. A composition comprising the combination of adenosine derivative and melatonin for treating and preventing neuro-degenerative disease. KR0103927; 2013
   Google Scholar
• Morozova MA, Beniashvili AG, Zapolskii ME. Combination for the prophylaxis treatment of behavioural, mental, and cognitive disorders. WO054965; 2014
   Google Scholar
• Jeong JK, Moon MH, Lee YJ, et al. Melatonin-induced autophagy protects against human prion protein-mediated neurotoxicity. J Pineal Res 2012;53:138-46
   PubMed Web of Science ®Google Scholar
• Industrial Cooperation Foundation Chonbuk National University. Novel uses of melatonin. WO109016; 2013
   Google Scholar
• Industry-Academic Cooperation Foundation, Yonsei University. Pharmaceutical composition for preventing or treating protein aggregate-inducing diseases. KR0014801; 2014
   Google Scholar
• Kanno H, Ozawa H, Sekiguchi A, et al. The role of mTOR signaling pathway in spinal cord injury. Cell Cycle 2012;11:3175-9
   PubMed Web of Science ®Google Scholar
• Nestec SA. Methods for reducing neurodegeneration. US0113949; 2014
   Google Scholar
• Wilhelmsen M, Amirian I, Reiter RJ, et al. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 2011;51:270-7
   PubMed Web of Science ®Google Scholar
• Cecype Services S. DE R.L. DE C.V. Pharmaceutical composition comprising a combination of a non-steroidal anti-inflammatory agent, an adjuvant and an antineuritic analgesic, having an antinociceptive effect. WO098552; 2014
   Google Scholar
• Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 2013;17:1483-96
   PubMed Web of Science ®Google Scholar
• Clinical trial identifier NCT01965522 Anti-proliferative effects of vitamin D and melatonin in breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01965522
   Google Scholar
• Clinical trial identifier NCT00668707 Adjuvant melatonin for prevention of lung cancer recurrence and mortality. Available from: https://clinicaltrials.gov/ct2/show/NCT00668707
   Google Scholar
• Ekmekcioglu C. Expression and putative functions of melatonin receptors in malignant cells and tissues. Wien Med Wochenschr 2014;164:472-8
   PubMedGoogle Scholar
• Grant SG, Melan MA, Latimer JJ, Witt-Enderby PA. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 2009;11:e5
   Web of Science ®Google Scholar
• Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzales C, Reiter RJ. Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Investig Drugs 2012;21:819-31
   PubMed Web of Science ®Google Scholar
• Duquesne University of the Holy Spirit. Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer. US8618083; 2013
   Google Scholar
• Duquesne University of the Holy Spirit. Anti-cancer tamoxifen-melatonin hybrid ligand. US8785501; 2014
   Google Scholar
• Scott & White Healthcare. Melatonin-based treatment and diagnosis of bile duct disease. US0079680; 2014
   Google Scholar
• Han Y, Demorrow S, Invernizzi P, et al. Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol 2011;301:G623-33
   PubMed Web of Science ®Google Scholar
• Clinical trial identifier NCT01557478 Melatonin as adjuvant therapy in breast cancer patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01557478
   Google Scholar
• Universidad de Granada. Use of melatonin for treating and/or preventing mucositis. US0243384; 2014
   Google Scholar
• Ruiqiong R. Vulcanized aspartic acid modified melatonin derivative and application thereof. CN102816103; 2014
   Google Scholar
• Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011;51:1-16
   PubMed Web of Science ®Google Scholar
• Luchetti F, Canonico B, Betti M. Melatonin signaling and cell protection function. FASEB J 2010;24:3603-24
   PubMed Web of Science ®Google Scholar
• Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, et al. Melatonin: buffering the immune system. Int J Mol Sci 2013;14:8638-83
   PubMed Web of Science ®Google Scholar
• University of Sunderland. Melatonin derivatives and their use as antioxidants. US8258173; 2012
   Google Scholar
• Iasomai AB. New combination comprising N-acetyl-L-cysteine and its use. WO130609; 2012
   Google Scholar
• Nutri-Fit GMBH. Melatonin and its use in preventing postoperative complications. US0249198; 2014
   Google Scholar
• Yang Y, Sun Y, Yi W, et al. A review of melatonin as a suitable antioxidant against myocardial ischemia-reperfusion injury and clinical heart diseases. J Pineal Res 2014;57:357-66
   PubMed Web of Science ®Google Scholar
• Tianjin Pacific Pharmaceutical. Traditional Chinese medicine composition used for treating low immunity in middle-aged and elderly people. CN102872294; 2013
   Google Scholar
• Slominski AT, Kleszczynski K, Semak I, et al. Local melatoninergic system as the protector of skin integrity. Int J Mol Sci 2014;15:17705-32
   PubMed Web of Science ®Google Scholar
• Universidad de Granada. Composition comprising melatonin or its derivatives with coenzyme Q10 and use thereof against ageing of the skin. WO083227; 2014
   Google Scholar
• Mavi Sud s.r.l. Melatonin and immunostimulating substance-based compositions. US8802117; 2014
   Google Scholar
• Novaera s.r.l. Melatonin and an antimicrobial or antibacterial agent for the treatment of acne. US0199413; 2014
   Google Scholar
• Suzhou Guli Biotechnology Co. Skin whitening cream. CN102860978; 2013
   Google Scholar
• Luchetti F, Canonico B, Bartolini D, et al. Melatonin regulates mesenchymal stem cell differentiation: a review. J Pineal Res 2014;56:382-97
   PubMed Web of Science ®Google Scholar
• Maria S, Witt-Enderby PA. Melatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting procedures. J Pineal Res 2014;56:115-25
   PubMed Web of Science ®Google Scholar
• Duquesne University of the Holy Spirit. Enhanced bone healing. US0029960; 2013
   Google Scholar
• Riukowski JL. Formulations and methods for recovery from dental surgery. EP2711012; 2014
   Google Scholar
• Sun Yat-Sen University. Application of melatonin synergistic extracellular matrix biomaterial to preparation of medicament for promoting osteoblast differentiation of mesenchymal stem cells. CN103736150; 2014
   Google Scholar
• Sun Yat-Sen University. Application of melatonin in preparation of drugs for promoting mesenchymal stem cell chondrogenic differentiation. CN103494808; 2014
   Google Scholar
• Medical College of Georgia, University of South Florida. Method of disease-induced and receptor-mediated stem cell neuroprotection. US0009271; 2012
   Google Scholar
• Brzozowska I, Strzalka M, Drozdowicz D, et al. Mechanisms of esophageal protection, gastroprotection and ulcer healing by melatonin. implications for the therapeutic use of melatonin in gastroesophageal reflux disease (GERD) and peptic ulcer disease. Curr Pharm Des 2014;20:4807-15
   PubMed Web of Science ®Google Scholar
• De Souza Pereira R. Method using a dietary supplement for healing or regressing symptoms of gastroesophageal reflux disease, gastritis and ulcers. US0090305; 2013
   Google Scholar
• De Souza Pereira R. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. J Pineal Res 2006;41:195-200
   PubMed Web of Science ®Google Scholar
• Obshchestvo S Ogranichennoj Otvetstvennost’ju “Ehr Ehnd Di Farma”. Pharmaceutical composition for gastric and/or duodenal ulcer. RU2010129474; 2012
   Google Scholar
• Celinski K, Konturek SJ, Konturek PC, et al. Melatonin or L-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole. J Pineal Res 2011;50:389-94
   PubMed Web of Science ®Google Scholar
• Clinical trial identifier NCT01566474 Melatonin associated to acid inhibition for chemoprevention in barret esophagus: a pilot study. Available from: https://clinicaltrials.gov/ct2/show/NCT01566474
   Google Scholar
• Nestec SA. Methods for increasing absorption of peptides, peptidomimetics and other gastrointestinal transport protein substrates. US8492331; 2013
   Google Scholar
• Navarro-Alarcón M, Ruiz-Ojeda FJ, Blanca-Herrera RM, et al. Melatonin and metabolic regulation: a review. Food Funct 2014;5:2806-32
   PubMed Web of Science ®Google Scholar
• Korea Food Research Institute. Composition of food components for appetite control comprising specific compounds as effective component. KR0046967; 2012
   Google Scholar
• Korea Food Research Institute. Composition for promoting leptin secretion comprising specific compounds as effective component. KR0010192; 2013
   Google Scholar
• Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood pressure regulation. Int J Mol Sci 2014;15:17920-37
   PubMed Web of Science ®Google Scholar
• Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 2011;7:577-84
   PubMedGoogle Scholar
• Neurim Pharma 1991. Method and formulation for treating resistance to antihypertensives and related conditions. US8075914; 2011
   Google Scholar
• Obshchestvo S Ogranichennoj Otvetstvennost’ju “Ehr Ehnd Di Farma”. Pharmaceutical composition for treating and/or preventing arterial hypertension. RU2010129473; 2012
   Google Scholar
• Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008;44:26-40
   PubMed Web of Science ®Google Scholar
• Kemp DM, Ubeda M, Habener JF. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic-cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol 2002;191:157-66
   PubMed Web of Science ®Google Scholar
• Takahashi JS, Kay SA. Compositions and methods for diabetes treatment. US0232003; 2012
   Google Scholar
• Wang F, Tian X, Zhang L, et al. Melatonin promotes the in vitro development of pronuclear embryos and increases the efficiency of blastocyst implantation in murine. J Pineal Res 2013;55:267-74
   PubMed Web of Science ®Google Scholar
• Tamura H, Takasaki A, Miwa I, et al. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J Pineal Res 2008;44:280-7
   PubMed Web of Science ®Google Scholar
• Maxia N. Use of N-acetyl-5-methoxytriptamine or analogs thereof, for promoting the mechanism of implantation of the embryo and related compositions and culture media. WO178587; 2013
   Google Scholar
• Olcese J, Beesley S. Clinical significance of melatonin receptors in the human myometrium. Fertil Steril 2014;102:329-35
   PubMed Web of Science ®Google Scholar
• The Florida State University Research Foundation, Inc. Methods of treating pre-term labor. US0088057; 2014
   Google Scholar
• Astellas Pharma, Inc. Pharmaceutical composition for treating or preventing stress urinary incontinence or mixed incontinence, and method for screening compounds to be included in said pharmaceutical composition. WO010603; 2014
   Google Scholar
• Gomez-Pinilla PJ, Gomez MF, Swärd K, et al. Melatonin restores impaired contractility in aged guinea pig urinary bladder. J Pineal Res 2008;44:416-25
   PubMed Web of Science ®Google Scholar
• Rassoulian D. Use of melatonin to treat acute alcohol intoxication. EP2570126; 2014
   Google Scholar
• Mor M, Rivara S, Pala D, et al. Recent advances in the development of melatonin MT1 and MT2 receptor agonists. Expert Opin Ther Patents 2010;20:1059-77
   PubMed Web of Science ®Google Scholar
• Hardeland R, Cardinali DP, Srinivasan V, et al. Melatonin-A pleiotropic orchestrating regulator molecule. Prog Neurobiol 2011;93:350-84
   PubMed Web of Science ®Google Scholar
• Rodríguez-Franco MI, Fernández-Bachiller MI, Pérez C, et al. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem 2006;49:459-62
   PubMed Web of Science ®Google Scholar
• López-Iglesias B, Pérez C, Morales-García JA, et al. New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer’s disease. J Med Chem 2014;57:3773-85
   PubMed Web of Science ®Google Scholar
• Fernández-Bachiller MI, Pérez C, Campillo NE, et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer’s disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem 2009;4:828-41
   PubMed Web of Science ®Google Scholar
• Ochoa-Sanchez R, Comai S, Lacoste B, et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci 2011;31:18439-52
   PubMed Web of Science ®Google Scholar
• Noseda AC, Rodrigues LS, Targa AD, et al. Putative role of monoamines in the antidepressant-like mechanism induced by striatal MT2 blockade. Behav Brain Res 2014;275:136-45
   PubMed Web of Science ®Google Scholar